Balchem Corporation — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports fourth-quarter results. Balchem develops and sells specialty ingredients and products across food and nutrition, animal health, and medical sterilization markets.
Financial performance
| Metric | FY2014 | FY2013 |
|---|---|---|
| Net sales | $541.4 million | $337.2 million |
| Gross margin | $144.2 million; 26.6% of sales | $97.4 million; 28.9% of sales |
| Earnings from operations | $82.1 million; 15.2% of sales | $65.6 million; 19.5% of sales |
| Net earnings | $52.8 million | $44.9 million |
| Diluted EPS | $1.69 | $1.45 |
| Cash from operating activities | $85.4 million | $55.7 million |
- FY2014 revenue increased 60.6%; the May acquisition of SensoryEffects contributed $156.2 million of sales for the period it was owned.
- Fourth-quarter sales were $162.7 million versus $81.6 million in Q4 2013; net earnings were $19.0 million versus $10.7 million, and diluted EPS was $0.61 versus $0.35.
- FY2014 sales by segment: Animal Nutrition & Health (ANH) $281.2 million, SensoryEffects $206.1 million, and Specialty Products $54.1 million. ANH sales rose 17.9%, led by ruminant nutrition, feed-grade choline, and industrial applications; SensoryEffects sales include the acquired business from May 7 onward.
- Cash and cash equivalents were $50.3 million at year-end, down from $208.7 million. Working capital was $85.8 million, versus $242.0 million. Current assets were $181.3 million and current liabilities $95.5 million.
- Debt was $332.5 million, including $35.0 million current; the company had $100 million of undrawn revolving capacity. The secured loans mature May 7, 2019; the stated interest rate was 1.92% at year-end, and the company reported compliance with quarterly covenants.
Material changes and unusual items
- Balchem acquired all of Performance Chemicals & Ingredients Company (SensoryEffects) on May 7, 2014. Total acquisition-date payments were approximately $569 million, funded in part through a $350 million term loan and a $50 million revolver draw. The purchase added substantial goodwill and acquired intangibles.
- Gross and operating margins declined year over year. Management cited acquired products’ lower gross margins, a $4.7 million acquired-inventory fair-value charge, acquired-intangible amortization, product mix, and $3.7 million of transaction and integration expenses. A $2.9 million favorable net legal settlement partly offset operating expenses.
- Interest expense rose to $5.1 million from $0.02 million, principally due to acquisition financing. FY2014 capital expenditures were $13.2 million, compared with $8.2 million in 2013.
- The company reported $52.8 million of net earnings and $85.4 million of operating cash flow; investing activities used $504.4 million, principally reflecting the acquisition and capital spending.
Outlook, risks, and contingencies
- Management expected operations to generate sufficient cash to fund working capital and necessary investment, and said it was pursuing further acquisition candidates. Planned 2015 capital expenditures were $30–$40 million. All $38.8 million of year-end backlog was expected to ship during 2015.
- Management emphasized integration, production efficiencies, broader product applications, and growth in human and animal health markets. No specific revenue or earnings guidance was provided.
- Key exposures include raw-material price and availability, competition, operating interruptions, foreign exchange, and demand sensitivity in certain industrial products to oil-and-gas activity. Approximately 22% of 2014 sales were outside the United States.
- EPA registration reviews for ethylene oxide and propylene oxide could entail further testing or affect permitted uses. Management expected their uses to continue, but a loss of required registrations could materially harm the Specialty Products business. FDA oversight and third-party cGMP manufacturing also pose risks for pharmaceutical products.
- Environmental matters include ongoing discussions with New York regulators regarding the Slate Hill site; any additional action was expected to be limited, with recent monitoring costs below $5,000 annually. The company said other litigation outcomes were not expected to materially affect its financial position, results, or liquidity. A $5.2 million uncertain-tax-position liability was recorded; settlement timing was not reasonably estimable.
- Goodwill was $383.6 million at year-end. Annual impairment testing found reporting-unit fair values above carrying amounts, based on estimates including future growth, margins, discount rates, and market conditions.
Important facts for investors to verify
- How SensoryEffects performs after acquisition, including realized synergies, integration costs, and the effect of amortization on reported margins and earnings.
- Debt repayment capacity and covenant headroom, especially if operating cash flow or acquisition spending changes.
- Whether margin recovery is achievable despite acquired-product mix and raw-material cost volatility.
- Progress and potential requirements in EPA reviews, and any developments in the Slate Hill environmental matter or uncertain tax positions.
- Execution of the $30–$40 million 2015 capital plan and conversion of the year-end backlog into sales.